Published in Gene Therapy Weekly, February 21st, 2008
"We evaluated whether targeting NF-kappa B could be of therapeutic and prognostic values in human RCC. The activation of the NF-kappa B pathway in human RCC cells and tumors was investigated by Western blot. In vitro, the effects of BAY 117085 and sulfasalazine, two NF-kappa B inhibitors, on tumor cell growth were investigated by cell counting, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide analysis, terminal...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.